AU2010278302B2 - MUC1 antibodies - Google Patents

MUC1 antibodies Download PDF

Info

Publication number
AU2010278302B2
AU2010278302B2 AU2010278302A AU2010278302A AU2010278302B2 AU 2010278302 B2 AU2010278302 B2 AU 2010278302B2 AU 2010278302 A AU2010278302 A AU 2010278302A AU 2010278302 A AU2010278302 A AU 2010278302A AU 2010278302 B2 AU2010278302 B2 AU 2010278302B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
cancer
derivative
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010278302A
Other languages
English (en)
Other versions
AU2010278302A1 (en
Inventor
Antje Danielczyk
Steffen Goletz
Uwe Karsten
Renate Stahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2010278302A1 publication Critical patent/AU2010278302A1/en
Application granted granted Critical
Publication of AU2010278302B2 publication Critical patent/AU2010278302B2/en
Assigned to DAIICHI SANKYO CO., LTD. reassignment DAIICHI SANKYO CO., LTD. Request for Assignment Assignors: GLYCOTOPE GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2010278302A 2009-07-31 2010-07-30 MUC1 antibodies Active AU2010278302B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
EP09009942.5 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
US61/230,211 2009-07-31
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Publications (2)

Publication Number Publication Date
AU2010278302A1 AU2010278302A1 (en) 2012-02-09
AU2010278302B2 true AU2010278302B2 (en) 2014-12-18

Family

ID=41460131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010278302A Active AU2010278302B2 (en) 2009-07-31 2010-07-30 MUC1 antibodies

Country Status (17)

Country Link
US (1) US9217038B2 (cg-RX-API-DMAC7.html)
EP (3) EP2281844A1 (cg-RX-API-DMAC7.html)
JP (2) JP5922018B2 (cg-RX-API-DMAC7.html)
KR (1) KR101773506B1 (cg-RX-API-DMAC7.html)
CN (1) CN102574926B (cg-RX-API-DMAC7.html)
AR (1) AR077334A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010278302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012002226A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768888C (cg-RX-API-DMAC7.html)
CU (1) CU23972B1 (cg-RX-API-DMAC7.html)
EA (1) EA029954B1 (cg-RX-API-DMAC7.html)
IL (1) IL217827A (cg-RX-API-DMAC7.html)
MX (1) MX2012000874A (cg-RX-API-DMAC7.html)
NZ (1) NZ597563A (cg-RX-API-DMAC7.html)
SG (2) SG177527A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011012309A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200166B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2603528B1 (en) 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CN105008550B (zh) * 2013-03-01 2018-03-30 学校法人埼玉医科大学 包含对muc4基因多态性进行检测的步骤的、判定抗癌剂疗法的副作用的发生风险的方法
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015119180A1 (ja) * 2014-02-06 2015-08-13 医化学創薬株式会社 ムチン4(muc4)糖ペプチドに対する抗体及びその用途
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗muc1抗体又はその抗原結合性断片及びその用途
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトMUC1抗体Fabフラグメント
JP7162011B2 (ja) * 2017-01-18 2022-10-27 ナノクルーズ・ファーマシューティカル・リミテッド 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3601357A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
CN110382541A (zh) 2017-03-29 2019-10-25 葛莱高托普有限公司 人源化抗cd40抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
KR102832078B1 (ko) * 2017-10-24 2025-07-08 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc1抗体およびその使用
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗muc1抗體-藥物結合物投予的藥劑低敏感性癌之治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) * 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
WO1993020841A1 (en) 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Muc−1抗原に対する治療用抗体およびその使用方法
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) * 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DANIELCZYK A. et al, PankoMab: a potent new generation anti-tumour MUC1 antibody, Cancer Immunology, Immunotherapy, 2006, Vol. 55(11), pg. 1337-1347 *

Also Published As

Publication number Publication date
CN102574926B (zh) 2014-10-15
IL217827A0 (en) 2012-03-29
KR20120051724A (ko) 2012-05-22
CA2768888A1 (en) 2011-02-03
US20120128676A1 (en) 2012-05-24
EP2281844A1 (en) 2011-02-09
AU2010278302A1 (en) 2012-02-09
IL217827A (en) 2017-05-29
SG10201404019XA (en) 2014-09-26
NZ597563A (en) 2013-08-30
SG177527A1 (en) 2012-02-28
EP3421497A1 (en) 2019-01-02
EA201270207A1 (ru) 2012-07-30
AR077334A1 (es) 2011-08-17
WO2011012309A8 (en) 2011-04-07
MX2012000874A (es) 2012-02-01
JP2016041771A (ja) 2016-03-31
CU20120019A7 (es) 2012-06-21
BR112012002226A2 (pt) 2016-11-08
JP6272916B2 (ja) 2018-01-31
WO2011012309A1 (en) 2011-02-03
CU23972B1 (es) 2013-12-27
CN102574926A (zh) 2012-07-11
KR101773506B1 (ko) 2017-08-31
JP5922018B2 (ja) 2016-05-24
ZA201200166B (en) 2013-03-27
US9217038B2 (en) 2015-12-22
JP2013500703A (ja) 2013-01-10
EP2459595A1 (en) 2012-06-06
EA029954B1 (ru) 2018-06-29
CA2768888C (en) 2019-02-26

Similar Documents

Publication Publication Date Title
US9217038B2 (en) MUC1 antibodies
CN112601762B (zh) 抗cd47抗体及其应用
Wels et al. Construction, bacterial expression and characterization of a bifunctional single–chain antibody–phosphatase fusion protein targeted to the human ERBB–2 receptor
JP7533898B2 (ja) 血中半減期の向上のための抗体Fc変異体
TWI708788B (zh) 雙特異性抗體
TWI719966B (zh) 結合cd47之抗體治療劑
KR101477762B1 (ko) 특이성 결합 단백질 및 용도
EP4083072A1 (en) Muc1* antibodies
CN112449641A (zh) 抗-muc1抗体
CN113480657B (zh) 针对her2的单域抗体及其衍生蛋白和应用
WO2012020059A1 (en) Humanized egfr antibodies
JP2022521956A (ja) Bcmaに結合する抗原結合性タンパク質
TWI714895B (zh) 抗csf-1r抗體、其抗原結合片段及其醫藥用途
WO2022075439A1 (ja) 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
AU2024402617A1 (en) Antibodies against cd24
JP2018510150A (ja) Jag1に結合する抗体医薬
JP2025531360A (ja) 分離した抗原結合タンパク質及びその使用
EP4613774A1 (en) Single domain antibody targeting human ror1
KR20250007549A (ko) Nk 세포종양 치료제
HK40082756A (en) Muc1* antibodies
CN119546636A (zh) FcRn-结合多肽及其用途
CN121449745A (zh) 靶向baff-r的全人源抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: DAIICHI SANKYO CO., LTD.

Free format text: FORMER OWNER(S): GLYCOTOPE GMBH